Last Price$61.4(0.0%)
Market Cap$7,773.1M
EV/FCF LTM
17.6x
5Y avg
3.2x
Biotechnology industry
median
(0.6x)
Stock quality & Intrinsic value
8/10
(0.1%) overvalued
Halozyme Therapeutics, Inc. EV/FCF LTM
Annual
Quarterly
Daily
Crunching data... Almost there!
| Dec'05 | Dec'06 | Dec'07 | Dec'08 | Dec'09 | Dec'10 | Dec'11 | Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EV/FCF LTM | (8.2x) | (42.3x) | 20.7x | (10.6x) | (12.4x) | (14.1x) | (31.9x) | (10.7x) | (32.3x) | (16.9x) | (90.0x) | (22.6x) | (76.9x) | 19.4x | (42.0x) | (246.6x) | 21.5x | 37.4x | 16.4x | 17.6x |
Overvalued or undervalued?
Check the intrinsic value for HALO
and see if it's the right time to invest.
Halozyme Therapeutics, Inc. (HALO) EV/FCF LTM comparison analysis
General
LTM EV/FCF LTM
OTHER METRICS
Company name
Revenue growth
EPS growth
Net Income margin
Halozyme Therapeutics, Inc.HALO
18.5x
22.4%
64.3%
43.7%
Median Peer Set
(0.1x)
14.8%
(19.3%)
7.5%
BioMarin Pharmaceutical Inc.BMRN
27.1x
18.0%
139.3%
15.0%
Regeneron Pharmaceuticals, Inc.REGN
17.0x
8.3%
10.4%
31.1%
United Therapeutics CorporationUTHR
10.0x
23.6%
25.7%
41.5%
Royalty Pharma plcRPRX
7.4x
(3.8%)
(43.7%)
37.9%
BeiGene, Ltd.BGNE
(0.2x)
73.7%
467.1%
(35.9%)
BioNTech SEBNTX
(23.7x)
(77.4%)
(89.7%)
24.4%
Summit Therapeutics Inc.SMMT
(90.8x)
N/A
(68.7%)
N/A
Vertex Pharmaceuticals IncorporatedVRTX
(152.4x)
11.7%
N/A
(4.9%)
Alnylam Pharmaceuticals, Inc.ALNY
(688.3x)
23.0%
(38.6%)
(12.4%)
argenx SEARGX
N/A
198.6%
(60.5%)
(24.1%)
HALO key stats
USD
Millions
Billions
Annual
Quarterly
Trailing
Key stats
Income statement
Balance sheet
Cash Flow Statement
Valuation
Ratios
Per share
Per employee
Dividends & Yields
| Dec'05 | Dec'06 | Dec'07 | Dec'08 | Dec'09 | Dec'10 | Dec'11 | Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
% growth | 0.1 0.0% | 1.0 671.8% | 3.8 287.0% | 8.8 130.7% | 13.7 56.0% | 13.6 (0.3%) | 56.1 311.7% | 42.3 (24.5%) | 54.8 29.5% | 75.3 37.5% | 135.1 79.3% | 146.7 8.6% | 316.6 115.8% | 151.9 (52.0%) | 196.0 29.1% | 267.6 36.5% | 443.3 65.7% | 660.1 48.9% | 829.3 25.6% | 1,015.3 22.4% |
| Cost of Goods Sold (COGS) | 0.1 | 0.4 | 0.2 | 0.3 | 0.3 | 1.0 | 0.3 | 1.1 | 6.2 | 22.7 | 29.2 | 33.2 | 31.2 | 10.1 | 45.5 | 43.4 | 81.4 | 139.3 | 192.4 | 159.4 |
% margin | 0.1 59.1% | 0.5 55.5% | 3.6 93.7% | 8.4 96.2% | 13.4 97.7% | 12.6 92.8% | 55.8 99.5% | 41.2 97.4% | 48.6 88.6% | 52.6 69.8% | 105.8 78.3% | 113.5 77.4% | 285.5 90.2% | 141.7 93.3% | 150.4 76.8% | 224.2 83.8% | 361.9 81.6% | 520.8 78.9% | 636.9 76.8% | 855.9 84.3% |
| Operating Expenses | 13.6 | 16.1 | 31.7 | 58.9 | 71.8 | 66.9 | 75.7 | 94.9 | 129.0 | 115.6 | 133.3 | 196.7 | 204.5 | 211.1 | 218.1 | 80.0 | 86.0 | 253.3 | 299.3 | 304.4 |
| Research & Development Expenses (R&D) | 10.2 | 9.2 | 20.6 | 44.2 | 56.6 | 51.8 | 57.6 | 70.0 | 96.6 | 79.7 | 93.2 | 150.8 | 150.6 | 150.3 | 140.8 | 34.2 | 35.7 | 66.6 | 76.4 | 79.0 |
| Selling, General & Administrative Expenses (SG&A) | 3.4 | 6.9 | 11.2 | 14.6 | 15.2 | 15.1 | 18.1 | 24.8 | 32.3 | 35.9 | 40.0 | 45.9 | 53.8 | 60.8 | 77.3 | 45.7 | 50.3 | 143.5 | 149.2 | 154.3 |
% margin | (13.6) (10,660.7%) | (15.6) (1,587.3%) | (28.2) (740.9%) | (50.4) (575.5%) | (58.5) (427.6%) | (54.3) (398.2%) | (19.8) (35.4%) | (53.6) (126.7%) | (80.4) (146.8%) | (63.0) (83.7%) | (27.5) (20.3%) | (83.2) (56.7%) | 81.0 25.6% | (69.3) (45.7%) | (67.6) (34.5%) | 144.3 53.9% | 275.9 62.2% | 267.5 40.5% | 337.6 40.7% | 551.5 54.3% |
| Interest Income | 0.0 | 0.0 | 0.0 | 1.7 | 0.1 | 0.0 | 0.0 | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 7.1 | 15.0 | 6.4 | 15.9 | 0.0 | 0.0 |
| Interest Expense | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 3.3 | 5.6 | 5.2 | 20.0 | 22.0 | 18.0 | 11.6 | 20.4 | 7.5 | 16.9 | 18.8 | 18.1 |
| Pre-tax Income | (13.3) | 0.0 | 0.0 | (48.7) | (58.4) | (53.2) | (19,769.9) | (53.6) | (83.5) | (68.4) | (32.2) | (101.9) | 61.6 | (79.8) | (72.3) | 129.3 | 248.5 | 248.9 | 348.3 | 557.1 |
% effective tax rate | (0.3) 2.2% | (0.8) 0.0% | (4.3) 0.0% | (0.1) 0.1% | 0.0 0.0% | (1.0) 1.9% | (1.2) 0.0% | (1.1) 2.1% | 2.0 (2.5%) | 3.8 (5.6%) | 3.5 (10.9%) | 1.2 (1.1%) | (1.4) (2.2%) | 0.5 (0.7%) | (0.0) 0.0% | 0.2 0.2% | (154.2) (62.0%) | 46.8 18.8% | 66.7 19.2% | 113.0 20.3% |
% margin | (13.3) (10,435.9%) | (14.8) (1,502.6%) | (23.9) (628.9%) | (48.7) (555.2%) | (58.4) (426.9%) | (53.2) (390.8%) | (19.8) (35.2%) | (53.6) (126.5%) | (83.5) (152.3%) | (68.4) (90.8%) | (32.2) (23.9%) | (103.0) (70.2%) | 63.0 19.9% | (80.3) (52.9%) | (72.2) (36.9%) | 129.1 48.2% | 402.7 90.8% | 202.1 30.6% | 281.6 34.0% | 444.1 43.7% |
| EPS | (0.26) | (0.24) | (0.32) | (0.61) | (0.67) | (0.56) | (0.19) | (0.48) | (0.74) | (0.56) | (0.25) | (0.81) | 0.46 | (0.56) | (0.50) | 0.95 | 2.86 | 1.48 | 2.13 | 3.50 |
| Diluted EPS | (0.26) | (0.24) | (0.32) | (0.61) | (0.67) | (0.56) | (0.19) | (0.48) | (0.74) | (0.56) | (0.25) | (0.81) | 0.45 | (0.56) | (0.50) | 0.91 | 2.74 | 1.44 | 2.10 | 3.43 |
% margin | (13.4) (10,498.5%) | (14.5) (1,477.8%) | (28.2) (740.9%) | (49.4) (563.5%) | (56.9) (416.3%) | (52.7) (387.2%) | (18.7) (33.3%) | (52.5) (124.0%) | (79.0) (144.1%) | (61.0) (81.0%) | (25.4) (18.8%) | (79.5) (54.2%) | 83.2 26.3% | (69.3) (45.7%) | (56.6) (28.9%) | 153.0 57.2% | 259.0 58.4% | 315.5 47.8% | 451.9 54.5% | 656.5 64.7% |
Discover more Stock Ideas
Undervalued stocks right now
Discover the top 20 best undervalued stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
3M Return 32.1%
S&P Outperformance 19.1%
Next 3M Predicted Return 20.3%
Undervalued growth stocks
Discover the top 20 best undervalued large-cap growth stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
3M Return 35.3%
S&P Outperformance 22.3%
Next 3M Predicted Return 26.8%
Undervalued dividend stocks
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Mar 2025.
3M Return 28.4%
S&P Outperformance 15.4%
Next 3M Predicted Return 16.9%
FAQ
1) What is Halozyme Therapeutics, Inc.'s EV/FCF LTM?
As of today, Microsoft Corp's last 12-month EV/FCF LTM is 17.6x, based on the financial report for Dec 30, 2024 (Q4’2024). The average annual EV/FCF LTM for Halozyme Therapeutics, Inc. have been 25.1x over the past three years, and 3.4x over the past five years.
2) Is Halozyme Therapeutics, Inc.'s EV/FCF LTM Good?
As of today, Halozyme Therapeutics, Inc.'s EV/FCF LTM is 17.6x, which is higher than industry median of (0.6x). It indicates that Halozyme Therapeutics, Inc.'s EV/FCF LTM is Bad.